Os modelos experimentais reproduzem doenças que acometem seres humanos, sendo de extrema importância porque possibilitam o estudo da patogênese e abordagem terapêutica dessas enfermidades. Nesse grupo inclui-se o modelo experimental de esclerodermia induzida pela imunização de coelhos com colágeno V humano provocando alterações histológicas (pele, pulmão e rim) similares àquelas observadas em humanos. As doenças auto-imunes têm sua etiologia desconhecida e são particularmente caracterizadas pela presença de auto-anticorpos no soro. Nesse aspecto, 90 a 95% dos pacientes com esclerodermia apresentam algum auto-anticorpo contra antígenos intracelulares (proteínas nucleolares RNA polimerase I, II e III, Scl-70, centriolares ou golginas) ou da matriz extracelular (colágeno). O presente estudo tem como objetivo avaliar a resposta imunológica nos animais do modelo experimental de esclerodermia. Para tanto, o soro dos animais foram testados quanto à presença de auto-anticorpos e de outros fatores imunológicos séricos que indicassem um processo imunológico ativo paralelo às lesões teciduais em desenvolvimento e incluiu: pesquisa de anticorpos anticolágenos V, III e I, imunocomplexos circulantes, fator reumatóide, níveis de complemento, fatores antinucleares (FAN) por imunofluorescência indireta em células HEp-2 e caracterização dos antígenos alvos por immunoblot. A análise da resposta imune revelou que as alterações histológicas do pulmão, rim e pele se desenvolviam com o aumento dos níveis séricos de anticorpos anti-colágeno V. Além disso, todos os animais imunizados com Col V apresentavam anticorpos para outros tipos de colágeno. Esses animais desenvolveram uma marcante resposta imunológica a antígenos intracelulares com 100% de positividade para o FAN e presença de imunocomplexos nos soros obtidos 30, 75 e 120 dias pós-imunização quando comparados a dois grupos controles (albumina e adjuvante completo de Freud). Todos os animais do grupo Col V apresentaram na IFI padrão citoplasmático Golgi símile e, em 10% deles, reatividade adicional aos centríolos. Ambos auto-anticorpos são raros, mas já descritos em pacientes com esclerodermia. A pré-absorção dos soros desses animais com Col V não interferiu no resultado do FAN. A caracterização dos antígenos alvos mostrou uma reatividade uniforme a proteínas de alto peso molecular de células epiteliais humanas (maior ou igual 175 kDa) que progredia com o tempo de imunização. Eluatos ácidos contendo os anticorpos anti-fração 175 kDa reproduziram o padrão de IFI igual ao soro original. As análises demonstram que a imunização com Col V humano em coelhos resulta numa resposta imunológica exuberante e que se caracteriza pela presença de auto-anticorpos a componentes intracelulares. / Experimental models for human diseases are of utmost importance, since they allow the study of their pathogenesis and therapeutic approach. In this group we can include the experimental model of collagen V-induced scleroderma, in rabbits, with histological alterations (skin, lung and kidney) similar to those observed in humans. Auto-immune diseases have an unknown etiology, and are characterized by the presence of auto-antibodies in serum. In this aspect, 90%-95% of the patients with scleroderma present some kind of auto-antibody against intracellular antigens (RNA polymerase I, II and III nucleoproteins, Scl-70, centriolar or golgins) or to components of the extracellular matrix (collagen). This study aims to assess the immune response of the animal subjects in a scleroderma experimental model. The animals sera were tested for auto-antibodies and other serum immunological factors that would point to an active immunological process, parallel to the developing tissue lesions, including anti-collagen V, III and I antibodies, circulating immune complexes, rheumatoid factor, complement levels, antinuclear antibodies (ANA) by indirect immunofluorescence in HEp-2 (IFI) cells, and characterization of target antigens with an immunoblot. The analysis of the immune response in the studied animals revealed that histological alterations in lungs, kidneys and skin developed with an increase of the serum levels of anti-collagen V antibodies. Furthermore, all the Col Vimmunized animals presented antibodies against other types of collagen as well. These animals also developed a strong immune response against intracellular antigens, being 100% positive for ANA, showing also immune complexes in sera obtained 30, 75 and 120 days after immunization with Col V, when compared to the control groups (albumin and Freunds complete adjuvant). All the animals from the Col V group showed a cytoplasmic pattern at the IFI, Golgi simile and, in 10% of the cases, additional reactivity to the centrioles. Both auto-antibodies are rare, yet were already described in patients with scleroderma. The pre-absorption of these animals sera with Col V did not interfere with the ANA reactivity. The characterization of the target antigens showed a uniform reactivity to high molecular weight proteins of human epithelial cells (> or = 175 kDa), which progressed with the immunization time. Acid eluats containing antibodies against the 175 kDa fraction reproduced the same IFI reactivity pattern of the original serum. The results demonstrate that immunization of rabbits with human Col V results in an exuberant immune response, characterized by the presence of autoantibodies against intracellular components.

Foram imunizados 27 macacos-prego (Cebus apella), por via intramuscular, com vacina anti-rábica inativada, produzida a partir de cérebros de camundongos lactentes (VARCCL), empregada nas campanhas de prevenção da raiva animal de cães e gatos. Os animais permaneceram em cativeiro, durante o período de junho de 1995 a junho de 1997, sendo divididos em 3 grupos experimentais e vacinados conforme o esquema: grupo I, com 3 doses a intervalo de 30 dias; o II, com 2 doses a intervalo 30 dias e reforço aos 210 dias; e, o III com uma dose e reforço aos 210 dias. A revacinação anual foi realizada em todos os animais aos 365 dias. As amostras de soros foram obtidas aos 0, 30, 60, 90, 150, 210, 240, 300, 365, 395, 545 e 730 dias, e armazenadas à temperatura de -20ºC, e a dosagem dos anticorpos realizada através do teste simplificado da inibição da fluorescência. Verificou-se que os animais do grupo I apresentaram soroconversão mais duradoura (12232 dias) do que os dos grupos II e III (p<0,05) após a vacinação inicial, e os animais do grupo I apresentaram soroconversão mais duradoura (183,6120,6 dias) do que os dos grupos II (p<0,05), após a revacinação anual aos 365 dias. A VARCCL induziu a resposta imune nos macacos-prego, após vacinação e revacinação, respectivamente, em 81,4 por cento e 76,0 por cento dos animais; com produção de anticorpos neutralizantes, iguais ou superiores a 0,5 UI/ml, porém, de curta duração; não constituindo assim, imunógeno apropriado para ser utilizado na rotina de imunização destes animais de difícil lide, mantidos em cativeiro / Twenty-seven capuchin monkeys (Cebus apella) were intramuscularly immunized with inactivated suckling mouse brain rabies vaccine (SMBV) employed in campaigns for animal rabies prevention in dogs and cats. The animals were kept confined from June, 1995 to June, 1997. They were divided into 3 experimental groups and vaccinated according to the following scheme: group I, with 3 doses within a 30-day interval; group II, with 2 doses within a 30-day interval and a booster dose at the 210th day; and, group III; with a single dose and a booster dose at the 210th day. All animals were given the annual re-vaccination at the 365th day. Sera samples were obtained at the 0th, 30 th, 60th, 90 th, 150 th, 210 th, 240 th, 300 th, 365 th, 395 th, 545 th e 730 th days and kept stored at 20ºC. The antibodies dosage was carried out through the simplified inhibition fluorescent test. The following results were observed: animals belonging to group I had longer humoral immune response (12232 days) than the ones belonging either to group II or group III (p<0.05) after initial vaccination; animals of group I presented longer humoral immune response (183.6120.6 days) than the ones of the group II (p<0.05) after the annual re-vaccination at the 365th day. The SMBV induced humoral immune response in capuchin monkeys after vaccination and re-vaccination in respectively 81.4 per cent and 76.0 per cent of the animals, producing neutralizing antibodies equal to or higher than 0.5 IU/ml; however, they were short-lasting, being therefore not appropriate as an immunogen to be used routinely in the immunization of these animals which are difficult both to be deal with and to be held confined

Le paludisme est l’une des maladies infectieuses la plus fréquente au monde avec 40% de la population mondiale exposée. En dépit des stratégies actuelles de lutte notamment la prise en charge rapide des cas, l’utilisation de matériaux imprégnés et la pulvérisation intra domiciliaire d’insecticide, le paludisme reste une des premières causes de morbidité et de mortalité notamment en Afrique subsaharienne. Cette partie du monde totalise à elle seule plus de 90% des cas de décès par paludisme dont 88% chez les enfants de moins de moins de 5 ans. En absence de vaccin utilisable en santé publique, il y a donc un besoin urgent de trouver une stratégie efficiente et simple de contrôle du paludisme. Le traitement préventif intermittent (TPI) définie comme l’administration d’un antipaludique à dose curative à des intervalles de temps prédéfinis réduit l’incidence du paludisme et apparaît aujourd’hui comme une des stratégies les plus prometteuses. Cette stratégie couplée au Programme Elargi de Vaccination (PEV) chez les enfants de moins de 1 an réduit l’incidence du paludisme de 30%. Des résultats plus importants sont obtenus chez les enfants de 0 à 5 ans voire de 0 à 10 ans lorsque la stratégie est appliquée en ciblant la saison de transmission. Nos travaux de recherche au Mali ont porté sur :- l’impact de la mise en œuvre du TPI couplé à la vaccination du PEV (TPin) sur i) la résistance P. falciparum à la Sulfadoxine pyrimethamine (SP), ii) la couverture des vaccins du PEV, iii) le taux de mortalité des enfants âgés de 4 à 18 mois.- l’efficacité du TPI chez les enfants ciblant la saison de transmission (TPIe) dans un contexte de faible et de forte couverture en des Moustiquaires Imprégnés d’Insecticides (MII). Nos résultats ont montré qu’après une année de mise en œuvre à l’échelle du district sanitaire, le TPIn a entrainé une augmentation de la couverture des vaccins du PEV. Cette couverture était de 53% en zone de non-intervention contre 69.5% en zone d’intervention (p<0.01). Il y a eu une réduction de la mortalité globale de 27% (RR= 0,73, IC95% : 0,55-0,97, p=0,029) chez les enfants âgés de 4 à 18 mois. Les fréquences des marqueurs moléculaires de la résistance de P. falciparum à SP en début et en fin la mise en œuvre et entre la zone d’intervention et la zone de non –intervention après une année de mise en œuvre étaient similaires. Deux doses de SP données en TPI à 8 semaines d’ intervalle durant la saison de transmission réduit le taux d’incidence du paludisme pendant la saison de transmission de 69,4% chez les enfants de moins de 5 ans et de 63,4% chez les enfants de 5-10 ans dans un contexte de très faible utilisation de MII (<5%). Dans une autre étude que nous avons menée, le TPI avec SP + Amodiaquine (AQ) donné en 3 occasions à un mois d’ intervalle pendant la saison de transmission a réduit le taux d’ incidence du paludisme clinique non compliqué de 82% (IC à 95%: 78%– 85%; P<0.001) et les formes graves de paludisme de 87% (IC à 95% 42% – 99%, P=0.001) chez les enfants âgés de 3 à 59 mois en dépit un taux d’utilisation des MII de plus de 99%. Nous n’avons pas documenté d’événement indésirable grave lié à l’utilisation de la SP ou de la SP + AQ en TPI durant ces deux études. Nos résultats étayent la recommandation du TPI, ciblant la saison de transmission ou couplée au PEV, pour la lutte antipaludique chez les enfants. / Malaria is one of the most common infectious diseases in the world and 40% of the world population is exposed to malaria. Despite the current control strategies such as rapid diagnosis and treatment of disease cases, use of insecticide impregnated materials and indoor residuals spraying with insecticides, malaria remained a main cause of morbidity and mortality particularly in sub Saharan Africa. More than 90% of the deaths due to malaria occurred in this region and 88% of these deaths occurred in children aged less than 5 years of age. In absence of vaccine that can be used in public health, there is an urgent need for a simple and efficient control strategy. Malaria intermittent preventive treatment (IPT) defined as the administration of curative dose of anti-malarial drug at predefined time intervals, appears as one of the most promising strategies. Given through the Expanded Program of Immunization (EPI), the strategy reduced the incidence of malaria by 30%. More drastic reductions were obtained in children aged 0-5 years and even 0-10 years when the malaria transmission season was targeted for the administration of the strategy. Our research work in Mali has assessed the following:- The impact of implementation of IPT administrated through EPI (IPTi) on: i) the resistance of P. falciparum to Sulfadoxine pyrimethamine (SP); ii) EPI vaccine coverage, and iii) mortality of children of 4-18 months of age. - The efficacy of IPT in children targeting the malaria transmission season (IPTe) in a context of low and high coverage of insecticide impregnated nets (ITN).We have found that the implementation of IPTi at the district level has resulted in an augmentation of the EPI vaccine coverage. The EPI vaccine coverage was 53% in the non-intervention zone compared to 69.5% in the intervention zone (p<0,01). There was a reduction in all cause mortality of 27% (RR= 0.73, 95% CI : 0.55-0.97, p=0.029) in children aged 4-18 months. The frequencies of molecular markers of the resistance of P. falciparum to SP were similar at the beginning and the end of the one year implementation period and between the intervention and non-intervention zones.Two doses of SP given at 8 weeks interval during the transmission season, reduced the incidence of malaria episodes during the transmission season by 69.4% in children aged less than 5 years and by 63.4% in children aged 5-10 years in a context of very low ITN use (<5%). In another study that we have conducted, IPT with SP + Amodiaquine (AQ) given at three occasions at one month interval during the transmission season reduced the incidence rate of clinical malaria by 82% (95% CI: 78%– 85%; P<0.001), and the incidence of severe and complicated malaria by 87% (95% IC 42% – 99%, P=0.001) in children aged 3 to 59 months of age despite an ITN use of greater than 99%.There was no serious adverse event related to the use of SP or SP+AQ in IPT during the two studies. Our results support the recommendation of IPT targeting the transmission season and IPT given through the EPI for malaria control in children.

本研究主要是針對投資型年金之資產負債管理作探討，其中是就規避利率風險對於資產負債管理上的影響以及分析資產配置最適化作為研究的架構，而所利用的研究方法乃是取決於建構利率隨機模型並輔以免疫理論與Markowitz投資組合理論，以期在規避利率風險的同時，亦能將資產配置達至最佳化。 首先，為實際模擬出符合現實經濟環境變動下的隨機利率期間模型，本研究利用C.I.R利率期間結構模型來建構年金保單期間的利率結構，並且由於投資型年金之保單價值的累積特性，因此本研究同時亦建構出連接保單價值的投資資產之報酬率型態，進而模擬出各期之現金流量以及各項投資資產的存續期間；再者，藉由Markowitz投資組合理論，以在免疫條件之限制下進行最適資產配置之評估。 最後，以某知名的保險公司所推出的投資型年金商品作為本研究之實證對象，透過模擬之方法，將研究模型中之各項參數予以評估，並且根據上述之研究過程將免疫理論與投資組合理論相連接，以檢視投資型年金商品在規避利率風險的狀態下，其最適之資產配置比例是否與現行法令之規範相牴觸，而能給予適時之建議。另外，由本實證結果可知，經由本研究的分析流程，可以有效地給予年金管理者規劃出年金資產負債管理時的最適投資組合比例，並且在增加外國投資資產時，更能有效的增加年金資產之報酬，同時也不影響保險法對於投資資產的比例與總金額之限制。再者，對於探討規避利率風險前後之資產組合之資產報酬之變化時，可以進一步了解到，當年金管理者在運用免疫策略來規避利率風險時，其所面對的風險成本之多寡，以作為制定避險決策時的依據。 / This research explores the asset-liability management (ALM) for the Investment-Link-Annuity. Two aspects investigated in this research are the interest rate risk and the optimal asset allocation. Moreover, the major issue investigated here is the trade-off between the optimal investment return and the hedge of interest rate risk. We refer this trade-off as ALM cost. By using stochastic interest rate model, Immunization theory and Portfolio Selection Model, we construct an ALM model to achieve the optimal asset allocation given on hedging the interest rate risk under the immunization strategies for the insurance company. First, we utilize the public trading data for investment market in Taiwan and in USA from 1985 to 2000 and the investment-link annuity product of a well-know insurance company in Taiwan to simulate the cash flow and demonstrate the implementation of our model. By analyzing different simulations under various scenarios, the empirical results are as the followings: 1.The ALM cost for immunization strategies is very small, and is estimated to be about 1% to 2%. Therefore, we suggest that insurance companies should start to undertake the asset liability management as soon as possible. 2.If relaxing the investment restrictions of Insurance Law or allowing insurance company to invest in foreign investment market, the overall investment return will be increased and the ALM cost will be reduced effectively.

壽險公司積極開發新商品以因應大量退休人口的需求，讓退休屋主得以所居住之房屋為抵押物，向金融機構貸款以獲得退休後之資金來源的反向房屋抵押貸款商品也應運而生。但這類的退休商品，除了讓壽險公司因人類平均壽命延長的現象而曝露在長壽風險的威脅下之外，其中所牽涉到之多樣的財務風險，也讓壽險公司在經營上面臨另外一個挑戰，但是反向房屋抵押貸款商品因其商品特性，似乎也可以提供壽險公司不同的風險分散的效果，有助於提升整體商品組合的避險效果。 本研究所提出之多因子免疫模型，可供壽險公司依照其所銷售之商品及所欲規避之風險，選擇一個最適的商品銷售數量，讓整個商品組合獲得最佳之避險效果。本研究透過多因子免疫模型進行數值分析，發現商品中加入反向房屋抵押貸款商品時，其避險效果明顯的優於未包含反向房屋抵押貸款之商品組合，顯見壽險公司發行反向房屋抵押貸款商品將有助於達到風險分散的效果，獲得更佳的避險成效。 關鍵字：長壽風險、財務風險、反向房屋抵押貸款、多因子免疫模型。 / Life insurance company try to meet the demand of the elder who has been retired by designing new products. The mortgage instruments to enable elderly homeowners to borrow by using the equity in their home as collateral, called “reverse mortgage”. With the launch this kind of product, life insurance company exposures in the threat of longevity and involves in others financial risks. However, the features of reverse mortgage may create the different effects of diversification for life insurance company to catch the better effects of hedging. We propose the Multi-Factors Immunization Approach to calculate the optimal product portfolio which attain the best hedging effects for life insurer by adjusting the number of units sold and recognizing the risks they want to hedge. We discover that the product portfolios which include reverse mortgage have the better hedging effects than these don’t include by numerical analysis. It is obviously that life insurer can acquire the effect of diversification and better hedging effects. Key words: Longevity risk, Financial risk, Reverse mortgage, Multi-factors immunization approach.

De nombreuses études suggèrent que linhibition de la voie alterne du complément de lhôte est nécessaire aux parasites hématophages pour leur permettre daccomplir leur repas sanguin. Une revue décrivant ces études a été publiée dans Developmental and Comparative Immunology (Schroeder et al., (2009) Dev. Comp. Immunol. 33, 5-13). Plusieurs études suggèrent que linhibition de la voie alterne de lhôte par les protéines salivaires de tiques est importante pour lacquisition du repas sanguin et la transmission subséquente de pathogènes à lhôte infesté. Confortant cette hypothèse, une protéine salivaire capable dinhiber la voie alterne du complément a été clonée chez la tique américaine Ixodes scapularis (Valenzuela et al., (2000) J. Biol. Chem. 275, 18717-18723). Cette protéine, appelée Isac, ne présente aucune homologie avec les autres molécules anti-complément connues à ce jour, suggérant que cette protéine a été acquise au cours de lévolution par un mécanisme dévolution convergente. En plus de cet aspect fondamental, Isac représente un candidat antigénique prometteur pour le développement dun vaccin anti-tique potentiellement capable dinduire le rejet de la tique et/ou de prévenir la transmission des pathogènes. Le but initial de cette thèse était didentifier le ou les homologue(s) de la protéine Isac de la tique américaine Ixodes scapularis chez la tique européenne Ixodes ricinus. De façon intéressante, deux séquences différentes ont été isolées du transcriptome des glandes salivaires de la tique I. ricinus (Daix et al., (2007) Insect Mol. Biol. 16 (2), 155-166). Lexpression de ces séquences a révélé quelles codent pour des protéines secrétées capables dinhiber la voie alterne du complément. Ces protéines ont été appelées IRAC I et II pour « Ixodes ricinus anti-complement protein I and II ». La caractérisation des IRACs à laide danticorps monoclonaux a permis de révéler que ces deux protéines sont exprimées de façon constitutive au sein des glandes salivaires de la tique Ixodes ricinus et sont sur-exprimées au cours du repas sanguin. Létude de lexpression des protéines IRAC I et IRAC II au sein de la population dIxodes ricinus a révélé que ces deux protéines sont des paralogues codés par des gènes différents et non par des allèles dun même locus. Enfin, des analyses phylogéniques portant sur les différentes séquences codant pour les protéines homologues à Isac isolées chez les tiques Ixodes scapularis, Ixodes ricinus et Ixodes pacificus ont révélé que les tiques appartenant au complexe Ixodes ricinus codent pour une famille encore non décrite de molécules anti complément qui se sont diversifiées au cours de lévolution par un processus de sélection darwinienne positive. Les analyses phylogéniques des IRACs suggèrent que ces séquences ont subi une diversification par un processus de pression de sélection darwinienne positive, menant probablement à des molécules possédant des propriétés biologiques différentes. Dans la seconde étude, nous avons testé lhypothèse de travail selon laquelle chaque paralogue pourrait posséder des activités inhibitrices différentes à lencontre du complément de différentes espèces dhôtes naturels, contribuant ainsi à élargir le spectre dhôte des tiques I. ricinus. Les résultats obtenus démontrent que cette hypothèse est correcte (Schroeder et al., (2007) Microbes Infect. 9 (2), 247-250). Dans la troisième et dernière étude de ce manuscrit, nous avons testé le potentiel des protéines IRACs comme candidat antigénique pour le développement dun vaccin anti tique. Des recombinants de lherpèsvirus bovin 4 (BoHV-4) exprimant IRAC I ou IRAC II ont été produits. De façon intéressante, nous avons observé que bien que les recombinants BoHV-4 expriment de hauts taux de protéines IRACs fonctionnelles in vitro, les lapins immunisés à laide des recombinants BoHV-4 exprimant les IRACs ne développent pas de réponse humorale détectable à lencontre des transgènes. Dans le but daugmenter limmunogénicité des IRACs exprimés comme transgène, une seconde génération de recombinants BoHV-4 a été produite. Ceux-ci induisent lexpression des IRACs sous la forme de protéines de fusion transmembranaires à la surface des cellules infectées. Linoculation de ces recombinants à des lapins a engendré le développement dune forte réponse humorale à lencontre des IRACs. Néanmoins, cette réponse immune na pas engendré deffet majeur sur le repas sanguin de femelles Ixodes ricinus placées sur les lapins immunisés. / An increasing number of studies demonstrate that inhibition of host complement activation is crucial for completion of the blood feeding process of hematophagous parasites. A review of these studies has been published in Developmental and Comparative Immunology (Schroeder et al., (2009) Dev. Comp. Immunol. 33, 5-13). Several observations suggest that inhibition of the host complement alternative pathway by tick salivary proteins is crucial for the achievement of blood feeding and efficient transmission of the pathogens transmitted by the parasite. Strongly supporting this conclusion, a salivary protein able to inhibit the alternative pathway was cloned from the American tick Ixodes scapularis (Valenzuela et al., (2000) J. Biol. Chem. 275, 18717-18723). Interestingly, this molecule, termed Isac, has no similarity to any previously reported anti-complement molecules suggesting that it has been acquired through a mechanism of convergent evolution. In addition to this fundamental aspect, Isac is also a promising candidate antigen for the development of an anti-tick vaccine potentially able to induce the reject of the tick and/or to prevent the transmission of the pathogens. The initial goal of the present work was to clone the orthologue of Isac from the European tick Ixodes ricinus. Interestingly, two different sequences were isolated from the transcriptome of I. ricinus salivary glands (Daix et al., (2007) Insect Mol. Biol. 16 (2), 155-166). Expression of these sequences revealed that they both encode secreted proteins able to inhibit the complement alternative pathway. These proteins were called I. ricinus anticomplement (IRAC) protein I and II. Further characterization of IRACs using monoclonal antibodies revealed that both proteins are expressed constitutively in I. ricinus salivary glands and are up-regulated during blood feeding. Analysis of a series of individual ticks revealed that all ticks tested express both IRAC I and IRAC II, demonstrating that they are the products of different genes and not of alleles of the same locus. Finally, phylogenetic analyses of the I. ricinus IRAC I and II sequences together with homologues from I. scapularis and I. pacificus demonstrates that ticks belonging to the Ixodes ricinus complex encode a new family of relatively small anti-complement molecules undergoing diversification by positive Darwinian selection. Phylogenetic analyses of IRACs suggested that these sequences were diversifying by a process of positive Darwinian selection, possibly leading to molecules with different biological properties. In the second study, we tested the hypothesis that each paralogue may have different inhibitory activities against the complement of different natural host species, thereby contributing to broaden the host range of I. ricinus ticks. The data obtained demonstrated that this working hypothesis is correct (Schroeder et al., (2007) Microbes Infect. 9 (2), 247-250). In the third and last chapter of the present manuscript, we addressed the potential of IRAC I and II as candidate antigens for the development of an anti-tick vaccine. Bovine herpesvirus 4 (BoHV-4) recombinants expressing IRAC I or II were produced. Interestingly, we observed that although both recombinants expressed high levels of functional IRAC proteins in vitro, our attempts to immunize rabbits against IRACs via infection with these viruses invariably failed. In order to improve the immunogenicity of IRACs expressed as transgene, a second generation of BoHV-4 recombinants was produced. The latter expressed IRACs as transmembrane fusion proteins on cell surface. Comparison of the vaccine potential of BoHV-4 recombinant viruses expressing either secreted or transmembrane IRAC proteins revealed that while the former did not induce a detectable immune response against IRACs, the latter led to high titers of anti-IRAC antibodies. However, the immune response induced against IRACs did not lead to the reject of the tick but only slightly increased the duration of the blood feeding process.

The goal of this body of research was to elucidate the mechanism by which CD4+ T cells provide help for CD8+ cytotoxic T lymphocyte (CTL) responses in different immunization types. The establishment of diseases, such as chronic infections and cancers, is attributed to severe loss of or dysfunctions of CD4+ T cells. Even in acute infections, CD4+ T cell deficiency leads to poor memory responses. While the role of CD4+ T cells is being increasingly appreciated in these diseases, the timing and nature of CD4+ T help and associated molecular mechanisms are not completely understood. Growing evidence suggests that, depending on the type of infections or immunizations, the requirements of CD4+ T cells can vary for optimal CD8+ CTL responses. In order to understand the modulatory effects of CD4+ T cells for optimal CD8+ CTL responses, two distinct immunization types were chosen. These include: 1) non-inflammatory dendritic cell (DC) immunization, which fails to provide inflammatory/danger signals; and 2) inflammatory adenovirus (AdV) immunization, which provides profound inflammatory/danger signals. This allowed us to study CD4+ T cell’s participation under different inflammatory conditions. The studies described in Chapters 2 and 3 of this thesis were performed to further understand the concept of how CD4+ T cells mediate optimal CD8+ CTL responses. This has been called the “new dynamic model of CD4+ T helper – antigen (Ag)-presenting cells (Th-APCs),” proposed in 2005 by our laboratory. The study described in Chapter 2 shows that Th-APCs participate not only in augmenting CTL-mediated immune responses, perhaps during early phase, but also in regulating cellular immunity, perhaps during a later phase. Through enhanced IL-2, CD80 and CD40L singnaling, and weaker peptideMHC I (pMHC) signaling, Th-APCs stimulated naïve CD8+ T cells to differentiate into effector CTLs, capable of developing into, central memory CTLs. Th-APC-stimulated CD4+ T cells behaved like Th cells in function, augmenting the overall magnitude of CTL responses. In contrast, Th-APCs were able to kill DCs and other Th-APCs, predominantly through perforin-mediated pathway. The experiments described in Chapter 3 revealed a novel co-operative role of cognate Th-CTL interactions, contrary to previously known immune-regulatory mechanisms among Th-Th or CTL-CTL interactions. In our experiments, Th cells, via CD40L, IL-2, and acquired pMHC-I signaling, enhanced CTL survival and transition into functional memory CTLs. Moreover, RT-PCR, flow cytometry and western blot analysis demonstrate that increased survival of Th cell-helped CTLs is matched with enhanced Akt1/NF-κB activation, down-regulation of FasL and TRAIL, and altered expression profiles with up-regulation of prosurvival (Bcl-2) and down-regulation of proapoptotic (NFATc1, Bcl-10, Casp-3, Casp-4, Casp-7) genes/ molecules. Finally, helped CTLs were also able to induce protection against highly metastasizing tumor challenge, explaining why memory CTLs generated under cognate Th1’s help show survival and recall advantages. The studies in Chapter 4 showed how the precursor frequency (PF) of CD8+ T cells impacts CD4+ T helper requirements for functional CTL responses. At endogenous PF, CD4+ T helper signals were necessary for both primary and memory CTL responses. At increased PF, CD4+ T help, and its CD40L but not IL-2 signal became dispensable for primary CTL responses. In contrast, memory CTL responses required CD4+ T cell signals, largely in the form of IL-2 and CD40L. Thus, these results could impact the development of novel immunotherapy against cancers, since their efficacy would be determined in part by CD4+ T help and CD8+ T cell PF. Finally, the study showed the importance of CD4+ T cells for multiple phases of AdV transgene product-specific CTL responses. These include: a) cognate CD4+ T cells enhanced CTL responses via IL-2 and CD40L signaling during primary, maintenance and memory phases; b) polyclonal CD4+ T environment enhanced the survival of AdV-specific CTL survival, partially explaining protracted CTL contraction phase; and c) during the recall phase, the CD4+ T environment, particularly memory CD4+ T cells, considerably enhanced not only helped, but also unhelped, memory CTL expansion. Thus, these results suggest the participation of both cognate and polyclonal CD4+ T cells for multiple phases of AdV-specific CTLs. Taken together, the current work delineated the critical roles of CD4+ T cells in different stages of CTL responses and in the development of anti-tumor immunity. The results presented here will significantly advance our current understanding of immunity to cancers, autoimmunity and chronic infections, since pathogenesis of these diseases is largely determined by CD4+ T helper functions. As most immunization procedures use the principle that is based on functions of memory cells, the knowledge gained from this work will also have a major impact on designing vaccines against intractable diseases, including cancers and chronic infections. Moreover, in advanced tumors, vaccines developed using this knowledge may act synergistically with other cancer treatments such as irradiation, chemotherapy and microsurgery, minimizing their side effects and prolonging the lives of patients.

The invention of the vaccine has been one of the greatest public health triumphs of the modern world. Each new vaccine has saved thousands - even millions - of lives worldwide, but this success has been fraught with controversy over the safety and even the effectiveness of vaccines. Vaccines have not always had a spotless safety record, but today’s vaccines are incredibly safe and continue to protect millions of people against diseases that have significantly declined or nearly disappeared from the developing world. It is this very success that has led many people to forget, or never discover, what those diseases are and how destructive they can be. This report tells the story of several families whose lives were deeply affected by vaccine-preventable diseases, accompanied with images that help tell their story. Following these stories is a broader discussion of the issues related to vaccines, the misunderstandings and misinformation that often circulate about them, a brief mention of their safety and efficacy, and a general discussion of many of the diseases they can prevent. / text

Made available in DSpace on 2015-07-22T20:49:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-02-27 / Uma cisteína proteinase recombinante, rLdccys1, obtida pela expressão do gene Ldccys1 de Leishmania (Leishmania) chagasi em sistema bacteriano, foi utilizada em ensaios de imunodiagnóstico por ELISA e DTH em cães de uma região endêmica de leishmaniose visceral (LV), Teresina, Piauí. A rLdccys1 também foi utilizada para a imunização de cães e a avaliação da possível proteção dos animais imunizados contra o desafio com a L. (L.) chagasi. Os ensaios por ELISA dos soros de cães com LV mostraram que a sensibilidade para a detecção de anticorpos anti-L. (L.) chagasi utilizando a rLdccys1 e os extratos de promastigotas e amastigotas de L. (L.) chagasi foi de 98%, 86% e 89%, respectivamente. A rLdccys1 não apresentou reatividade cruzada com os soros de cães com doenças comuns nas regiões endêmicas de LV, tais como erliquiose, babesiose e doença de Chagas e a especificidade dos ensaios de ELISA utilizando-se a rLdccys1 e os extratos de amastigotas e promastigotas de L. (L.) chagasi foi de 96%, 69% e 68%, respectivamente. As respostas de DTH foram avaliadas nos cães após a injeção subcutânea da rLdccys1 ou do extrato dos amastigotas de L. (L.) chagasi. Todos os cães assintomáticos apresentaram resposta de DTH positiva à rLdccys1 com a formação de nódulos em torno de 10 mm 48 horas após a injeção do antígeno, enquanto que os cães sintomáticos não apresentaram reatividade significante à rLdccys1 nos ensaios de DTH. As respostas de DTH foram mais intensas quando se utilizou a rLdccys1 comparadas às observadas com o extrato dos parasitas. A análise histológica mostrou áreas de necrose e hemorragia nos nódulos induzidos pelo extrato dos parasitas e reação granulomatosa típica, com predomínio de células mononucleares, nos cortes dos nódulos induzidos pela rLdccys1. A análise dos dados obtidos nos ensaios de ELISA e DTH realizados com a rLdccys1 e os extratos de amastigotas de L. (L.) chagasi mostrou a correlação inversa entre as respostas humoral e celular no desencadeamento da LV canina. As respostas celulares induzidas nos cães pela rLdccys1 foram avaliadas após a imunização dos animais com o antígeno recombinante juntamente com a Propionibacterium acnes. Os linfócitos de sangue periférico dos cães imunizados com a rLdccys1 + P. acnes apresentaram significantes índices de estimulação quando reestimulados in vitro com a rLdccys1 ou o extrato dos amastigotas de L. (L.) chagasi. A dosagem de citocinas nos sobrenadantes dessas culturas mostrou a secreção de níveis significantes de IFN-γ, enquanto IL-10 não foi detectada. Nos experimentos em que cães foram imunizados com a rLdccys1 + P. acnes e desafiados com a injeção intraperitoneal de 1x104 amastigotas isolados de cão infectado com a L. (L.) chagasi 3 de 4 animais sobrevieram dez semanas após o desafio, enquanto que os animais controles que receberam PBS e a P. acnes morreram em no máximo 4 e 6 semanas, respectivamente, após o desafio. Nos cães imunizados com a rLdccys1 o número de amastigotas de L. (L.) chagasi foi significantemente reduzido no baço, fígado e medula óssea comparado ao observado nos controles. A dosagem sérica de IFN-γ nos animais imunizados com a rLdccys1 mostrou a secreção significante dessa linfocina, enquanto que níveis basais de IL-10 foram detectados. Todos os cães imunizados com a rLdccys1 e desafiados pela picada das fêmeas de Lutzomyia longipalpis sobreviveram até dezesseis semanas após o desafio e os animais controles injetados com PBS e P. acnes morreram sete e nove semanas, respectivamente, após o desafio. Os cães controles apresentaram número significante de amastigotas de L. (L.) chagasi no fígado e baço, porém nos animais imunizados com a rLdccys1 nenhum parasita foi observado. No grupo imunizado com a rLdccys1 houve aumento crescente dos níveis séricos de IFN-γ durante a imunização que atingiu um pico uma semana após o desafio, enquanto que e a concentração de IL-10 foi mantida em níveis basais. Os dados do presente trabalho mostraram o potencial da rLdccys1 de L. (L.) chagasi para o diagnóstico e a imunoprofilaxia da LV canina, abrindo perspectivas para a imunização dos cães em larga escala nas regiões endêmicas de LV e a avaliação do impacto da proteção conferida nos animais imunizados na incidência da doença. / A recombinant protein, rLdccys1, produced by expression of the gene encoding a 30 kDa cysteine proteinase from Leishmania (Leishmania) chagasi, was used to detect specific antibodies in serum by enzyme-linked immunosorbent assays and to test for reactivity in delayed-type hipersensitivity (DTH) responses of dogs from an endemic region of visceral leishmaniasis (VL), Teresina, Piauí State, Brazil. The recombinant protein was also used for immunization of dogs and evaluation of its possible protective role against L. (L.) chagasi infection. The sensitivity for detection of specific antibodies to L. (L.) chagasi using rLdccys1 and lysates from L. (L.) chagasi promastigotes and amastigotes was 96%, 68%, and 69%, respectively. No cross reactivity between rLdccys1 and Chagas disease was observed, and little reactivity was found with sera from dogs with babesiosis and ehrlichiosis. The specificity of ELISA assays using rLdccys1, lysates from L. (L.) chagasi promastigotes and amastigotes was 96%, 69%, and 68%, respectively. DTH responses were determined after subcutaneous injection of rLdccys1 or L. (L.) chagasi amastigote extract and the induration area was measured at 24, 48 and 72 h after injection. All asymptomatic dogs showed a positive intradermal response to rLdccys1 (10 mm) which peaked at 48 h, whereas no significant reactivity to the recombinant antigen was found in the symptomatic group. DTH responses to rLdccys1 were higher than those induced by amastigote extract. Histological analysis of the intradermal induration showed a predominance of necrotic and hemorrhagic areas in sections from asymptomatic dogs injected with L. (L.) chagasi amastigote extract, whereas a typical granulomatous reaction mediated by mononuclear cells was observed in sections from asymptomatic animals injected with rLdccys1. Data analysis from ELISA and DTH assays with rLdccys1 and L. (L.) chagasi amastigote extracts showed that humoral and cellular responses were inversely correlated during the development of canine VL. Cellular immune responses induced by the recombinant antigen were evaluated after immunization of dogs with rLdccys1 plus Propionibacterium acnes. Peripheral blood mononuclear cells isolated from rLdccys1-immunized dogs showed significant stimulation indexes after in vitro incubation with either rLdccy1 or L. (L.) chagasi amastigote extracts. Cytokine dosages in the supernatants from lymphocyte cultures showed significant levels of IFN-γ, whereas IL-10 was not detected. Whereas 3 from 4 dogs immunized with rLdccys1 plus P. acnes and challenged by intraperitoneal injection of 1x104 L. (L.) chagasi amastigotes survived ten weeks after challenge, control dogs which received either PBS or P. acnes died after four and six weeks, respectively. The load of L. (L.) chagasi amastigotes in spleen, liver, and bone marrow from rLdccys1-immunized dogs was significantly reduced in comparison to that of non immunized controls. A significant concentration of IFN-γ and basal levels of IL-10 were detected in sera from dogs immunized with rLdccys1. All dogs immunized with rLdccys1 plus P. acnes and challenged by the bite of L. (L.) chagas infected Lutzomyia longipalpis survived until sixteen weeks after challenge, whereas control dogs injected with PBS or P. acnes died after seven and nine weeks, respectively. Control dogs showed a significant number of L. (L.) chagasi amastigotes in liver and spleen, but no parasites were found in rLdccys1- immunized dogs. During immunization with rLdccys1 there was an increase of serum levels of IFN-γ in the immunized dogs that peaked one week after challenge. In contrast, a very low concentration of IL-10 was detected in these animals. Overall, these findings indicate that L. (L.) chagasi recombinant cysteine proteinase is potentially useful for diagnosis and immunoprophylaxis of canine VL. We believe that results obtained open perspectives for immunization of dogs in the field and evaluation of the impact on the disease incidence. / TEDE / BV UNIFESP: Teses e dissertações

Made available in DSpace on 2011-05-04T12:36:21Z (GMT). No. of bitstreams: 0 Previous issue date: 2009 / Considerando a carga e gravidade da Síndrome da Rubéola Congênita (SRC), uma campanha nacional de vacinação de mulheres com idade entre 12 e 39 anos foi realizada no Brasil em 2001-2002 com a meta de imunizar mais de 30 milhões de mulheres. A possibilidade de vacinar mulheres grávidas motivou a iniciativa de acompanhar gestantes vacinadas inadvertidamente (GVI) contra rubéola. Os objetivos do estudo foram descrever o estado imunológico das mulheres, detectar infecção congênita pelo vírus vacinal (ICR) e estimar o risco de SRC e ICR associado ao vírus vacinal. Realizou-se um estudo prospectivo não controlado no qual as taxas de SRC e ICR vacinais foram comparadas a dados históricos. O estudo foi conduzido em 7 Estados:Rio de Janeiro, São Paulo, Pernambuco, Minas Gerais, Bahia, Rio Grande do Sul e Goiás. Métodos laboratoriais incluíram teste sorológico rubéola-específico para IgM e IgG, PCR para detecção viral e seqüenciamento genômico para diferenciação viral. Uma GVI suscetível foi definida como aquela testada para rubéola até 30 dias após a vacinação e apresentou IgM positivo e IgG negativo. SRC associada à vacinação foi definida pela presença dos critérios da Organização Mundial da Saúde para a SRC em recém-nascidos de GVI suscetível, apresentando IgG+ e com vírus vacinal identificado. De um total de 16.435.776 mulheres vacinadas, 20.395 estavam grávidas no momento da vacinação. Destas, 2.330 (11,4 por cento) foram consideradas suscetíveis à rubéola. No acompanhamento de 1.797 recém-nascidos foram identificados 63 (3,5 por cento) IgM positivos configurando ICR. Os resultados das 2230 gestações em 5 Estados incluíram 80 (3,4 por cento) abortos e 11 (0,5 por cento) natimortos. Dados clínicos de 47 dos 63 casos de IRC mostraram 5 recém-nascidos com baixo peso, 4 prematuros, 1 comunicação inter-atrial e 1 sopro cardíaco aos 35 dias de vida, os quais não são compatíveis com SRC. A taxa de ICR foi de 3,5 por cento e nenhum caso de SRC foi detectado. Nossos dados reforçam as recomendações de (1) manter a contra-indicação de vacinação na gravidez e (2) não interromper a gravidez em caso de vacinação inadvertida. / Considering the burden and severity of Congenital Rubella Syndrome (CRS), a countrywide vaccination campaign was conducted in Brazil in 2001 and 2002 with the goal of immunizing over 30 million women aged 12 to 39 years. The possibility of vaccinating women unaware of their pregnancy prompted an initiative to identify and follow-up pregnant women inadvertently vaccinated (PWIV) against rubella. The objectives of this study were: to describe the immunological status of these women and ascertain vaccine virus infection in neonates born to women susceptible to rubella infection at the time of vaccination, and to estimate the risk of Congenital Rubella Infection (CRI) and CRS in neonates associated with the vaccine virus. This was a prospective uncontrolled study, in which rates of CRI and CRS due to the vaccine were compared with data from historic control group. The study was conducted in seven states of the country: Rio de Janeiro, São Paulo, Pernambuco, Minas Gerais, Bahia, Rio Grande do Sul, and Goiás. Laboratory methods included serum enzyme immune assay (EIA) for rubella IgM and IgG detection, PCR for viral detection and genomic sequencing for viral differentiation. A susceptible PWIV was defined as one tested for rubella within 30 days after vaccination and presented positive IgM and negative IgG. CRI associated with vaccination was defined as a newborn to a susceptible PWIV presenting with positive rubella IgM and having the vaccine virus identified but without CRS syndrome. CRS associated with vaccination was defined as a newborn to a susceptible PWIV who fulfilled the WHO criteria for CRS syndrome, presenting with positive rubella IgM and having the vaccine virus identified. From a total of 16,435,776 women, 20,395 were pregnant at the time of vaccination. Among these, 2,330 (11.4%) were considered susceptible at vaccination. The follow-up of 1,797 (77.1%) newborns disclosed 63 (3.5%) IgM positive, which was considered vaccine-associated CRI. Outcomes of 2,230 pregnancies in 5 states include 80 abortions (3.4%), and 11 stillborns (0.5%). Clinical data from 47 of the 63 CRI cases (75%) disclosed: 5 low birth weight, 4 preterm, 1 inter-atrium communication, and 1 cardiac murmur at 35 days of life, which are not compatible with CRS definitions. The rate of CRI was 3.5% and no CRS cases were detected. Our data support the recommendation (1) that pregnancy should remain a contraindication to vaccination and precautions should be taken to avoid vaccination within 28 days of vaccination; and (2) that in case vaccination occurs within 28 days of pregnancy, interruption of pregnancy should not be conducted.